{"public_id":"cl_bad18e713ec7982ecca07263f7ebae64","status":"active","superseded_by_public_id":null,"corpus_id":252457006,"text":"At 21 days after BNT162b2 booster administration in 48 ChAd/ChAd/BNT-vaccinated participants, all subjects achieved reactive/positive anti-SARS-CoV-2 IgG titers.","confidence":0.95,"paper":{"corpus_id":252457006,"title":"An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results","url":"https://sah.borca.ai/papers/252457006"},"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_64a7fc4ce9b439d8b53960a54e0b374b","name":"anti-SARS-CoV-2 immunoglobulin G","description":"Serum IgG antibodies directed against SARS-CoV-2 antigens, measured here by chemiluminescent immunoassay to evaluate humoral immune response after heterologous booster vaccination.","types":["antibody","biomarker"],"url":"https://sah.borca.ai/concepts/co_64a7fc4ce9b439d8b53960a54e0b374b"},{"public_id":"co_8f85fb6c49c7352b2bc6729086011db4","name":"BNT162b2","description":"An mRNA-based COVID-19 vaccine developed by Pfizer-BioNTech, administered here as the heterologous booster dose following ChAdOx1 primary vaccination.","types":["vaccine"],"url":"https://sah.borca.ai/concepts/co_8f85fb6c49c7352b2bc6729086011db4"},{"public_id":"co_afedb8596f96002a387dd2c987e64c3b","name":"heterologous ChAdOx1/BNT162b2 vaccination","description":"A mixed COVID-19 vaccination strategy in which two ChAdOx1 primary doses are followed by a BNT162b2 booster, designated ChAd/ChAd/BNT in this study.","types":["vaccination strategy"],"url":"https://sah.borca.ai/concepts/co_afedb8596f96002a387dd2c987e64c3b"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_bad18e713ec7982ecca07263f7ebae64"}